Adocia shares fall 6.5% after breaking through their €4.67 resistance level
The Lyon-based biotech is losing momentum after a spectacular surge, on the same day it unveils new preclinical data in diabetes and obesity. The move comes at the ObesityWeek congress in Washington, a scientific event the stock had been preparing for over several sessions.
A 6.5% decline to €4.37, testing the MM200 after a week of rally
Adocia shares fall 6.5% to €4.37 intraday, after gaining nearly 59% over the week.
The stock has just broken above its €4.67 resistance, reached in the last session, and is falling back below that level in today's decline. It remains well above its short-term moving averages, the MM20 at €3.15 and the MM50 at €2.98 (38.7% and 46.6% below the share price, respectively), and is testing the MM200, at €4.35.
The RSI at 70 signals an overbought configuration, which places today's decline within the logic of a very rapid rebound. The drop occurs in a Paris market barely moving higher: the CAC 40 gains 0.1%, while the stock is among the largest decliners on the exchange.
AdoXL Sema: preclinical data aimed at monthly semaglutide injection
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On November 16, 2026, Adocia unveiled preclinical data on AdoXL Sema, an application of its AdoXLong platform to semaglutide, at the ObesityWeek congress. Obtained in rats and pigs, these results support, according to the company, monthly administration in humans, with weight loss comparable to, and not superior to, that of the reference molecule.
The topic was known to investors: on November 9, the group had announced the presentation of a poster in Washington, from November 14 to 17.
On the financing side, cash stood at €8.4 million as of September 30, and the funding horizon was extended to the first quarter of 2028 following the €7 million transaction announced in October.
When it published its nine-month results on October 29, 2026, the company cited among its risks its dependence on a milestone payment of $20 million, conditional on the approval of BioChaperone Lispro in China.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -97 %
Guidance from the release
« Au 30 septembre 2026, la Société disposait d'une trésorerie de 8,4 millions d'euros qui lui permettait de financer ses activités jusqu'au début du deuxième trimestre 2027 » ; « Cette opération, en prenant en compte l'utilisation complète de la convention d'avance en compte courant, ainsi que la réduction des coûts initiée par la Société depuis septembre 2026, permet d'étendre l'horizon de trésor
Risks mentioned
Dépendance critique au paiement d'étape de 20 millions de dollars conditionné à l'obtention de l'AMM de BioChaperone Lispro en Chine
Besoin de financement à court ou moyen terme et capacité à lever des fonds supplémentaires
Incertitudes des données cliniques futures et de l'évolution des marchés du diabète et de l'obésité
Opportunities identified
Paiement d'étape de 20 millions de dollars sous condition de l'approbation de BC Lispro en Chine avec redevances à deux chiffres
Accords de collaboration R&D monétisés avec les entreprises pharmaceutiques pour tester librement la technologie BioChaperone
Extension de l'horizon de trésorerie jusqu'au T1 2028 (voire 2029 si AMM obtenue) grâce à la levée de 7 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.